-
1. CNS involvement in ATL. Cancer 1990; 65: 327.
Teshima T, et al.
-
2. Cytotoxic drugs and cytotoxic drugs/G-CSF mobilization of PBSCs and their use for autografting. Bone Marrow Transplant 1992;10: 215.
Teshima T, et al.
-
3. Hematopoietic progenitor cells from patient with ATL are not infected with HTLV-I. Blood 1993; 82: 2823.
Nagafuji K, et al.
-
4. BMT for EBV-associated NK cell-large granular lymphocyte leukemia. Lancet 1996; 372: 1124
Teshima T, et al.
-
5. IL-11 promotes T cell polarization and prevents acute GVHD after allogeneic BMT. J Clin Invest 1998; 102: 115.
Hill GR, et al.
-
6. IL-11 separates GVL effects from GVHD after BMT. J Clin Invest 1999; 104: 317.
Teshima T, et al.
-
7. Differential roles of IL-1 and TNF-α on GVHD and GVL. J Clin Invest 1999; 104: 459.
Hill GR, et al.
-
8. G-CSF-mobilized allogeneic SCT maintains GVL effects through a perforin dependent pathway while preventing GVHD. Blood 1999; 93: 4071.
Pan L, et al.
-
9. Keratinocyte growth factor separates GVL effects from GVHD. Blood 1999; 94: 825.
Krijanovski O, et al.
-
10. IL-18 regulates acute GVHD by enhancing Fas-mediated donor T cell apoptosis. J Exp Med 2001; 194: 1433.
Reddy P, et al.
-
11. LPS antagonism reduces GVHD and preserves GVL activity after BMT. J Clin Invest 2001; 107: 1581.
Cooke K, et al.
-
12. Tumor cell vaccine elicits potent anti-tumor immunity after allogeneic T-cell depleted BMT. Cancer Res 2001; 61: 162.
Teshima T, et al.
-
13. Acute GVHD does not require alloantigen expression on host epithelium. Nature Med 2002; 8: 575.
Teshima T, et al.
-
14. Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute GVHD. J Clin Invest 2002; 109: 1249.
Ordemann R, et al.
-
15. Flt3 ligand therapy for recipients of allogeneic BMT expands host CD8α+ dendritic cells and reduces acute GVHD. Blood 2002; 99: 1825.
Teshima T, et al.
-
16. DLI from immunized donors increases tumor vaccine efficacy after allogeneic BMT. Cancer Res 2002; 62: 796.
Teshima T, et al.
-
17. IL-18 preserves perforin dependent GVL effect after allogeneic BMT. Blood 2002; 100: 3429.
Reddy P, et al.
-
18. Impaired thymic negative selection causes autoimmune GVHD. Blood 2003; 102: 429.
Teshima T, et al.
-
19. Pretreatment of donors with IL-18 attenuates acute GVHD via STAT6 and preserves GVL effects. Blood 2003; 101: 2877.
Reddy P, et al.
-
20. Early changes in gene expression profiles of hepatic GVHD uncovered by ologonucleotide microarrays. Blood 2003; 102: 763.
Ichiba T, et al.
-
21. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute GVHD. Blood 2005; 105: 2023.
Maeda Y, et al.
-
22. Impact of HLA mismatch on GVHD and graft failure after reduced intensity conditioning allogeneic HSCT from related donors. Br J Haematol 2005; 130: 575.
Teshima T, et al.
-
23. Fetal tolerance to maternal antigens improves the outcome of allogeneic BMT by a CD4+CD25+ T cell-dependent mechanism. Blood 2006; 107: 404.
Matsuoka K, et al.
-
24. Donor-derived thymic-dependent T cells cause chronic GVHD. Blood 2007; 109: 1756.
Sakoda Y, et al.
-
25. Plasmacytoid dendritic cells prime alloreactive T cells to mediate GVHD as antigen-presenting cells. Blood 2009; 113: 2088.
Koyama M, et al.
-
26. Improved outcome of allogeneic BMT due to breast-feeding-induced tolerance to maternal antigens. Blood 2009; 113: 1829.
Aoyama K, et al.
-
27. Alloantigen expression on non-hematopoietic cells reduces GVL effects. J Clin Invest 2010; 120: 2370.
Asakura S, et al.
-
28. TIM-3 is a promising target to selectively kill AML stem cells. Cell Stem Cell 2010; 7: 708.
Kikushige Y, et al.
-
29. Th1 and Th17 join forces for acute GVHD. Blood 2011; 118: 4765
Teshima T
-
30. The Wnt agonist R-spondin1 regulates systemic GVHD by protecting intestinal stem cells. J Exp Med 2011; 208: 285.
Takashima S, et al.
-
31. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic HSCT. J Exp Med 2011; 208: 1069.
Hashimoto D, et al.
-
32. Regenerating islet-derived 3α is a biomarker of gastrointestinal GVHD. Blood 2011; 118: 6702.
Ferrara JL, et al.
-
33. Synthetic retinoid Am80 ameliorates chronic GVHD by downregulating Th1 and Th17. Blood 2012; 119: 285.
Nishimori H, et al.
-
34. Plasma biomarker of loser gastrointestinal and liver acute GVHD. Blood 2012; 119: 2960.
Harris AC, et al.
-
35. GVHD disrupts intestinal microbial ecology by inhibiting Paneth cell production of α-defensins. Blood 2012; 120: 223.
Eriguchi Y, et al.
-
36. Engulfment of hematopoietic stem cells caused by down-regulation of CD47 is critical in the pathogenesis of hemophagocytic lymphohistiocytosis. Blood 2012; 120: 4058.
Kuriyama T, et al.
-
37. Quantification of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic stem cell transplantation. Blood 2013; 121: 840.
39. Shima T, et al.
-
38. Evaluating the association between histological manifestations of cord colitis syndrome with GVHD. Bone Marrow Transplant 2013; 48: 1249.
Shimoji S, et al.
-
39. Reciprocal expression of enteric antimicrobial proteins in intestinal graft-versus-host disease. Biol Blood Marrow Transplant 2013; 19: 1525.
Eriguchi Y, et al.
-
40. Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood 2013; 122: 2125.
Aoyama K, et al.
-
41. Bone marrow graft-versus-host disease: evaluation of its clinical impact on disrupted hematopoiesis after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2014; 20: 495.
Shono Y, et al.
-
42. Expansion of donor-reactive host T cells in primary graft failure after allogeneic hematopoietic SCT following reduced-intensity conditioning. Bone Marrow Transplant 2014; 49: 110.
Koyama M, et al.
-
43. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 183.
Sugiyama H, et al.
-
44. JAK inhibitors: a home run for GVHD patients? Blood 2014; 123: 3691.
Teshima T.
-
45. Essential requirements for setting up a stem cell processing laboratory. Bone Marrow Transplant 2014; 49: 1098.
Leemhuis T, et al.
-
46. Graft-vs-Host Disease Working Committee of the CIBMTR. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation - A Report from CIBMTR. Biol Blood Marrow Transplant 2015; 21: 266.
Arai S, et al.
-
47. The primacy of IL-6 in IPS? Blood 2015; 125: 2320.
Teshima T.
-
48. α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. Blood 2015; 125: 3014.
Uryu H, et al.
-
49. Decreased secretion of Paneth cell α-defensin in graft-versus-host disease. Transpl Infect Dis 2015; 17: 702.
Eriguchi Y, et al.
-
50. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning. Biol Blood Marrow Transplant 2015; 21: 1646.
Sugita J, et al:
-
51. Allogeneic unrelated bone marrow transplantation from older donors results in worse prognosis in recipients with aplastic anemia. Haematologica 2016; 101: 644.
Arai Y, et al.
-
52. Soluble DNAM-1, as a Predictive Biomarker for Acute Graft-Versus-Host Disease. PLoS One 2016; 11: e0154173.
Kanaya M, et al.
-
53. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica 2016; 101: 1592.
Inamoto Y, et al.
-
54. Acute Graft-versus-Host Disease: Novel Biological Insights. Biol Blood Marrow Transplant 2016; 22: 11.
Teshima T, et al.
-
55. Graft-versus-host disease targets ovary and causes female infertility in mice. Blood 2017; 129: 1216.
Shimoji S, et al.
-
56. R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft-versus-host disease. J Exp Med 2017; 214: 3507.
Hayase E, et al.
-
57. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. Blood 2018; 131: 1476.
Yamakawa T, et al.
-
58. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood 2018;131:2074
Takahashi S, et al.
-
59. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 2018; 24: 282.
Mathew NR, et al.
-
60. JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 2019; 380: 45.
Schuster SJ, et al;
-
61. Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. Nat Commun 2019; 10: 1065.
Noviello M, et al.
-
62. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 2019; 25: 603.
Toffalori C, et al.
-
63. Lactose drives Enterococcus expansion to promote graft-versus-host disease. Science 2019; 366: 1143.
Stein-Thoeringer CK, et al.
-
64. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N Engl J Med 2020; 382: 822.
Peled JU, et al.
-
65. Intestinal goblet cells protect against GVHD after allogeneic stem cell transplantation via Lypd8. Sci Transl Med 2020; 12: eaaw0720.
Ara T, et al.
-
66. Mass screening of asymptomatic persons for SARS-CoV-2 using saliva. Clin Infect Dis 2020: ciaa1388.
Yokota I, et al.
-
1. 1999年 米国造血細胞移植学会 最高論文賞
-
2. 2016年 平成27年度北海道大学大学院医学研究科・医学部医学科 優秀研究賞
-
3. 2019年 日本造血細胞移植学会学会賞
-
4. 2020年 2020年度 第3回伊藤太郎学術賞・伊藤太郎特別賞
-
5. 2021年 令和2年度 北海道大学教育研究総長表彰
